New research reveals that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who end traditional diet and exercise plans.
Published data in a major health publication points out that while obese individuals often shed a large proportion of their total mass while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be informed of the risk of rapid weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass in about 18 months.
Analyzing Therapies
The research, which looked at 37 of trials involving thousands of participants, contrasted the results of the injectable medications with other pills.
The team note that people who shed pounds through dieting generally have a slower weight regain—approximately 100 grams monthly—once they finish.
Explaining the Fast Rebound
Nutrition scientists believe the mechanism of the jabs is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the high risk of weight regain, the therapy is often long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
People who have discontinued the jabs describe a intense return of cravings.
"It was like a switch flipping and I was suddenly starving," described a patient.
This difficulty is compounded if users have not developed permanent dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that a significant number of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is greater among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and long-term success relies on ongoing lifestyle support.
